Analystreport

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at B. Riley from $21.00 to $18.00.

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report